These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38396211)

  • 41. Central Unrelated Potential Bone Marrow and Cord Blood Registry in Poland: Structure and Numbers.
    Nestorowicz K; Dudkiewicz M; Czerwiński J; Łęczycka A; Macher M; Kamiński A
    Transplant Proc; 2020 Sep; 52(7):2011-2014. PubMed ID: 32499141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Encountering Challenges with the EU Regulation on Advance Therapy Medical Products.
    Mansnérus J
    Eur J Health Law; 2015 Dec; 22(5):426-61. PubMed ID: 26665690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monitoring the international use of unrelated donors for transplantation: the WMDA annual reports.
    Foeken LM; Green A; Hurley CK; Marry E; Wiegand T; Oudshoorn M;
    Bone Marrow Transplant; 2010 May; 45(5):811-8. PubMed ID: 20154736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Audits of collection and apheresis centers: guidelines by the World Marrow Donor Association Working Group Quality and Regulation.
    Lara-Weisshaupt E; Tistl I; Hale K; Torosian T; Schlaphoff T; Manor S; Jindra P; Schöffel-Weiß S; Audat F; Abress L; Pingel J
    Bone Marrow Transplant; 2019 Feb; 54(2):244-257. PubMed ID: 30108327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serious Stem Cell Donation Events and Recipient Adverse Reactions Related to Severe Acute Respiratory Syndrome Coronavirus 2: Review of Reports to the World Marrow Donor Association.
    Pawson R; Anthias C; Cody M; Fechter M; Fournier D; O'Flaherty E; Oliviera D; van Eerden E; Mengling T
    Transplant Cell Ther; 2023 Aug; 29(8):522.e1-522.e5. PubMed ID: 37271343
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System.
    Quinn C; Young C; Thomas J; Trusheim M;
    Value Health; 2019 Jun; 22(6):621-626. PubMed ID: 31198178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advanced therapy medicinal products: current and future perspectives.
    Hanna E; Rémuzat C; Auquier P; Toumi M
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance.
    Golay J; Pedrini O; Capelli C; Gotti E; Borleri G; Magri M; Vailati F; Passera M; Farina C; Rambaldi A; Introna M
    Cytotherapy; 2018 Feb; 20(2):262-270. PubMed ID: 29246649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A special report: suggested procedures for international unrelated donor search from the donor registries and quality assurance working groups of the World Marrow Donor Association (WMDA).
    Wiegand T; Raffoux C; Hurley CK; Kern M; Oudshoorn M; Raymond J; Cleaver S; Marry E; Muller C; ;
    Bone Marrow Transplant; 2004 Jul; 34(2):97-101. PubMed ID: 15170174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multivariate data analysis in cell gene therapy manufacturing.
    Emerson J; Kara B; Glassey J
    Biotechnol Adv; 2020 Dec; 45():107637. PubMed ID: 32980438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
    Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
    Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies.
    Scott M; Clarke D; Lipsitz Y; Brandwein H; Allickson J; Alzebdeh D; Aleksic S; Kraft C; Lhu L; Cornetta K
    Cytotherapy; 2020 Nov; 22(11):669-676. PubMed ID: 32713719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies.
    Shaw BE; Confer DL; Hwang W; Pulsipher MA
    Bone Marrow Transplant; 2015 Mar; 50(3):334-40. PubMed ID: 25599171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. World Marrow Donor Association framework for the implementation of HLA matching programs in hematopoietic stem cell donor registries and cord blood banks.
    Bochtler W; Maiers M; Bakker JN; Oudshoorn M; Marsh SG; Baier D; Hurley CK; Müller CR
    Bone Marrow Transplant; 2011 Mar; 46(3):338-43. PubMed ID: 20531286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The current state of the platelet supply in the US and proposed options to decrease the risk of critical shortages.
    Stubbs JR; Homer MJ; Silverman T; Cap AP
    Transfusion; 2021 Jan; 61(1):303-312. PubMed ID: 33098328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation.
    Shaw BE; Chapman J; Fechter M; Foeken L; Greinix H; Hwang W; Phillips-Johnson L; Korhonen M; Lindberg B; Navarro WH; Szer J
    Bone Marrow Transplant; 2013 Nov; 48(12):1506-9. PubMed ID: 23892330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association.
    Bitan M; van Walraven SM; Worel N; Ball LM; Styczynski J; Torrabadella M; Witt V; Shaw BE; Seber A; Yabe H; Greinix HT; Peters C; Gluckman E; Rocha V; Halter J; Pulsipher MA
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):96-103. PubMed ID: 26307344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Market access pathways for cell therapies in France.
    Rémuzat C; Toumi M; Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Classification of cell-based medicinal products and legal implications: An overview and an update].
    Scherer J; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.